Search results for "Glaucoma medication"

showing 3 items of 3 documents

The Size of Subconjunctival Preparation Does Not Influence the Outcome of Trabeculectomy With Mitomycin C

2014

PURPOSE To compare the outcome of fornix-based trabeculectomy with mitomycin C (MMC) using 2 different sizes of subconjunctival preparation (36 mm² compared with 72 mm²). METHODS Prospective, randomized interventional case series. STUDY POPULATION Patients 18 to 85 years of age with open-angle glaucoma and progressive visual field defects under maximum tolerated medical therapy were randomized to undergo initial fornix-based trabeculectomy with MMC (0.2 mg/mL for 5 min) with subconjunctival preparation of 6×6 mm (group A) or 8×9 mm (group B). Main outcome parameters were: intraocular pressure (IOP), best-corrected visual acuity (BCVA), number of 5-fluorouracil (5-FU) injections, and laser s…

MaleAlkylating Agentsmedicine.medical_specialtyIntraocular pressureVisual acuitygenetic structuresMitomycinmedicine.medical_treatmentVisual AcuityGlaucomaTrabeculectomyGroup BTonometry OcularPostoperative ComplicationsOphthalmologymedicineHumansTrabeculectomyProspective StudiesIntraocular PressureAgedAged 80 and overGlaucoma medicationbusiness.industryMitomycin CMiddle Agedmedicine.diseaseCombined Modality Therapyeye diseasesOphthalmologyTreatment OutcomePopulation studyFemaleFluorouracilsense organsmedicine.symptombusinessConjunctivaGlaucoma Open-AngleFollow-Up StudiesJournal of Glaucoma
researchProduct

Biodegradable collagen matrix implant versus mitomycin-C in trabeculectomy: five-year follow-up.

2015

Background Clinical studies comparing trabeculectomy augmented with Ologen implant (OLO) versus trabeculectomy plus mitomycin-C (MMC) show contradictory results. To obtain long-term data, we report an extended 5-year follow-up trial evaluating the safety and efficacy of OLO as adjuvant compared to low-dosage MMC in trabeculectomy. Methods Forty glaucoma patients (40 eyes) assigned to trabeculectomy with MMC or Ologen. Primary outcome: target IOP at ≤21, ≤17 and ≤15 mmHg; complete and qualified success endpoint rates. Secondary outcomes: visual acuity (VA), mean deviation (MD), bleb evaluation, according to Moorfields Bleb Grading System (MBGS); spectral domain OCT (SD-OCT) bleb examination;…

MaleIntraocular pressureVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityGlaucomaExfoliation Syndrome0302 clinical medicineAbsorbable ImplantsTrabeculectomyExtended 5-yrs follow-upExtended 5-yrs follow-up; Mitomycin-C; Ologen; Trabeculectomy;GlycosaminoglycansGeneral MedicineMiddle AgedMitomycin-CFemaleCollagenmedicine.symptomGlaucoma Open-AngleTomography Optical CoherenceHumanResearch ArticleAdultmedicine.medical_specialtyAlkylating AgentsMitomycinTrabeculectomyOlogenFollow-Up Studie03 medical and health sciencesAbsorbable ImplantOphthalmologymedicineHumansIntraocular PressureAgedSettore MED/30 - Malattie Apparato Visivobusiness.industryMitomycin CFive year follow upANTIGLAUCOMA MEDICATIONSAlkylating Agentmedicine.diseaseeye diseasesSurgeryOphthalmologyGlycosaminoglycan030221 ophthalmology & optometryImplantsense organsbusiness030217 neurology & neurosurgeryFollow-Up StudiesBMC ophthalmology
researchProduct

Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.

2010

. Purpose:  The purpose of this study was to investigate the tolerability and intraocular pressure (IOP) reducing effect of the first preservative-free prostaglandin tafluprost (Taflotan®) in patients exhibiting ocular surface side-effects during latanoprost (Xalatan®) treatment. Methods:  A total of 158 patients were enrolled in this open-label multicentre study. Eligible patients had to have at least two ocular symptoms, or one sign and one symptom, during treatment with latanoprost. At baseline, the patients were directly switched from latanoprost to preservative-free tafluprost for 12 weeks. The patients were queried for ocular symptoms, and ocular signs were assessed by using tear brea…

MaleIntraocular pressuregenetic structuresmedicine.medical_treatmentAdministration TopicalMucin 5ACmedicine.disease_causeExfoliation SyndromeConjunctival Diseaseschemistry.chemical_compoundSurveys and QuestionnairesMedicineLatanoprostAged 80 and overBlepharitisGeneral MedicineMiddle AgedTolerabilityPatient SatisfactionAnesthesiaProstaglandins F SyntheticLatanoprostFemalemedicine.symptomIrritationBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugAdultGonioscopyHyperemiaTonometry OcularHumansBlepharitisAntihypertensive AgentsIntraocular PressureAgedGlaucoma medicationbusiness.industryPreservatives PharmaceuticalProstaglandins FTafluprostHLA-DR Antigensmedicine.diseaseeye diseasesOphthalmoscopyOphthalmologychemistryQuality of LifeItchingOcular Hypertensionsense organsbusinessActa ophthalmologica
researchProduct